Search

Your search keyword '"Gerson SL"' showing total 309 results

Search Constraints

Start Over You searched for: Author "Gerson SL" Remove constraint Author: "Gerson SL"
309 results on '"Gerson SL"'

Search Results

12. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for relapsed non-Hodgkin's lymphoma: blood and bone marrow progenitor growth studies. A phase II Eastern Cooperative Oncology Group Trial

13. Hematopoietic stem cell gene therapy of murine protoporphyria by methylguanine-DNA-methyltransferase-mediated in vivo drug selection.

14. Unsuccessful Reexposure to Clozapine

15. Reduced lung tumorigenesis in human methylguanine DNA-methyltransferase transgenic mice achieved by expression of transgene within the target cell.

16. Release of granulocyte-specific colony-stimulating activity by human bone marrow exposed to phorbol esters

17. Modulation of nitrosourea resistance in myeloid leukemias

20. Combined HDAC8 and checkpoint kinase inhibition induces tumor-selective synthetic lethality in preclinical models.

21. Impact of age, antiretroviral therapy, and cancer on epigenetic aging in people living with HIV.

22. 15-PGDH regulates hematopoietic and gastrointestinal fitness during aging.

23. Identification of a Cancer-Predisposing Germline POT1 p.Ile49Metfs*7 Variant by Targeted Sequencing of a Splenic Marginal Zone Lymphoma.

24. Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed-Platinum-Radiation in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer: Results of a Phase I Trial.

25. An effective human uracil-DNA glycosylase inhibitor targets the open pre-catalytic active site conformation.

26. 15-PGDH inhibition activates the splenic niche to promote hematopoietic regeneration.

27. Status of Cancer Care at Network Sites of the Nation's Academic Cancer Centers.

28. Socioeconomic Factors and Survival of Multiple Myeloma Patients.

29. Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors.

30. Myeloid Krüppel-like factor 2 is a critical regulator of metabolic inflammation.

31. Protons and High-Linear Energy Transfer Radiation Induce Genetically Similar Lymphomas With High Penetrance in a Mouse Model of the Aging Human Hematopoietic System.

32. Inhibition of 15-PGDH Protects Mice from Immune-Mediated Bone Marrow Failure.

33. Mlh1 deficiency increases the risk of hematopoietic malignancy after simulated space radiation exposure.

34. Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma.

35. Gold Nanoparticle-Based Fluorescent Theranostics for Real-Time Image-Guided Assessment of DNA Damage and Repair.

36. Concise Reviews: Cancer Stem Cell Targeted Therapies: Toward Clinical Success.

37. High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer.

38. MMR Deficiency Does Not Sensitize or Compromise the Function of Hematopoietic Stem Cells to Low and High LET Radiation.

39. A second-generation 15-PGDH inhibitor promotes bone marrow transplant recovery independently of age, transplant dose and granulocyte colony-stimulating factor support.

40. Advances in therapeutic targeting of the DNA damage response in cancer.

41. Distinct roles of resident and nonresident macrophages in nonischemic cardiomyopathy.

42. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.

44. Loss of Uracil DNA Glycosylase Selectively Resensitizes p53-Mutant and -Deficient Cells to 5-FdU.

45. Long-Term Deficits in Behavior Performances Caused by Low- and High-Linear Energy Transfer Radiation.

46. New Opportunities and Challenges to Defeat Cancer Stem Cells.

47. New Advances and Challenges of Targeting Cancer Stem Cells.

48. Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies.

49. Mismatch repair deficient hematopoietic stem cells are preleukemic stem cells.

50. Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.

Catalog

Books, media, physical & digital resources